Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: penetratin conjugates - Cyclacel Pharmaceuticals

Drug Profile

Research programme: penetratin conjugates - Cyclacel Pharmaceuticals

Alternative Names: CYC 300

Latest Information Update: 16 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Peptides
  • Mechanism of Action DNA topoisomerase I inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Mar 2006 Xcyte Therapies has merged with Cyclacel to form Cyclacel Pharmaceuticals
  • 03 Mar 2006 This programme is still in active development
  • 02 Mar 2004 Compounds from the CYC300 research programme are available for licensing worldwide (http://www.cyclacel.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top